This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
<i>Candida</i>	Unknown	<p>Cell culture studies identified (S)-2-aminoalkyl benzimidazoles that could help treat <i>Candida</i> infections. In a panel of 16 <i>Candida</i> clinical isolates, the lead benzimidazole had a mean minimal inhibitory concentration of 2.83 µg/mL compared with 2.18 µg/mL for the antifungal fluconazole. In the same panel, the lead compound had antifungal activity against three fluconazole-resistant strains. EMC microcollections GmbH has the lead benzimidazole in preclinical testing to treat <i>Candida</i> infection.</p> <p>Diflucan fluconazole, a synthetic triazole antifungal from Pfizer Inc., is marketed to treat <i>Candida</i> infection.</p> <p>SciBX 4(30); doi:10.1038/scibx.2011.854 Published online Aug. 4, 2011</p>	Patented for use as an antimicrobial; licensing status undisclosed	<p>Bauer, J. <i>et al.</i> <i>J. Med. Chem.</i>; published online June 29, 2011; doi:10.1021/jm200571e</p> <p>Contact: Holger Eickhoff, EMC microcollections GmbH, Tuebingen, Germany e-mail: eickhoff@microcollections.de</p>